Stock CTNM CONTINEUM THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Contineum Therapeutics, Inc.

Equities

CTNM

US21217B1008

Market Closed - Nasdaq
Other stock markets
 03:59:51 2024-05-29 pm EDT 		5-day change 1st Jan Change
15.36 USD +4.49% Intraday chart for Contineum Therapeutics, Inc. -3.15% 0.00%
Apr. 30 Morgan Stanley Starts Contineum Therapeutics With Overweight Rating MT
Apr. 30 Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target MT

Evolution of the average Target Price on Contineum Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

92a3a6b81c1.SrWtU5Ssrg2MDGHHoy4YsyaKeJ4OzvERlgeHhvKwPpU.Fd76Zvni91TYO1Ookhtw4GLnE69dmLp_2TfUsbn7a_cV8p874Z_dbPtGFg~d56236cf2468c9169b0c41b26ef38281

Analyst Recommendations on Contineum Therapeutics, Inc.

Morgan Stanley Starts Contineum Therapeutics With Overweight Rating MT
Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target MT
RBC Initiates Contineum Therapeutics at Outperform, Speculative Risk With $30 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
15.35 USD
Average target price
28 USD
Spread / Average Target
+82.41%
High Price Target
30 USD
Spread / Highest target
+95.44%
Low Price Target
25 USD
Spread / Lowest Target
+62.87%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Contineum Therapeutics, Inc.

RBC Capital Markets
Stifel Nicolaus
Morgan Stanley

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CTNM Stock
  4. Consensus Contineum Therapeutics, Inc.